Nanoscan (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanoscan, is a plasma protein preparation presented as a sterile injectable solution for intravenous and subcutaneous use. It helps restore plasma oncotic pressure and serves as a carrier protein in patients requiring volume expansion or protein supplementation in critical care settings.

GNH USA supplies Nanoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Human serum albumin (Nanoscan) is employed in clinical situations where plasma protein support or volume expansion is required.

- Hypovolemia: restores intravascular volume and oncotic pressure in patients with acute blood loss or dehydration. - Severe hypoalbuminemia: raises serum albumin levels in liver disease, nephrotic syndrome or chronic malnutrition. - Burn injuries: supplies essential protein and assists fluid balance during extensive skin loss. - Cardiac surgery: supports hemodynamics during cardiopulmonary bypass and postoperative recovery. - Plasma exchange procedures: acts as a volume expander to maintain circulatory stability.

Human serum albumin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever or chills during infusion. - Mild hypotension or transient blood pressure drop. - Headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Localized erythema or mild urticaria at the injection site. - Transient increase in serum calcium.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Volume overload leading to pulmonary edema. - Hemolysis or severe hemolytic transfusion reaction. - Sepsis or bacterial contamination of the product. - Thromboembolic events in high‑risk patients.

Human serum albumin should be used with careful clinical assessment and monitoring.

- Allergy assessment: avoid in patients with known hypersensitivity to human albumin or any excipients. - Volume status: monitor for fluid overload, especially in cardiac or renal impairment. - Renal function: adjust infusion volume in patients with compromised kidney function. - Pregnancy and lactation: use only when clearly indicated after risk‑benefit evaluation. - Infusion rate: administer slowly and observe for signs of hypotension or reaction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human serum albumin can interact with other therapies that affect fluid balance or protein binding.

Major Interactions (Avoid): - Concurrent use with high‑dose diuretics may exacerbate hypovolemia. - Co‑administration with other volume expanders can precipitate fluid overload.

Moderate Interactions (Monitor Closely): - Albumin‑bound drugs (e.g., warfarin, certain antibiotics) may have altered free concentrations. - Simultaneous infusion of blood products may increase risk of volume overload. - Electrolyte solutions administered concurrently can affect serum electrolyte balance.